Alzheimers Disease Expert Offers Insight on ICAD Findings & What This Means For Patients & Caregivers Perspective on Data Presented at the 2010 International Conference on Alzheimers Disease (ICAD) in Honolulu, Hawaii (July 10-15)
What: The Alzheimers Associations annual International Conference on Alzheimers Disease (ICAD) is the largest group of international leaders in Alzheimers research and care, drawing approximately 5,000 researchers, physicians and care providers from around the world each year to tackle the issue of combating Alzheimers disease. The number of Americans suffering from Alzheimers disease continues to rise – by 2050, between 11 million and 15 million individuals aged 65 and older are projected to be living with Alzheimers disease, according to recent data from the Alzheimers Association. With Alzheimers disease touching so many Americans, your listeners may be interested to hear about the latest research just revealed at this years ICAD meeting, and what it means to both patients and caregivers. What can they expect in the next five years? And what can they be doing now?
The inside scoop on the findings at the 2010 ICAD
Perspective on recent failures of a number of investigational Alzheimers drugs, including Dimebon and bapineuzamab
New research and potential treatment options on the horizon
Results of a NIH sponsored study conducted by Dr. Atri revealing benefits of current medications
Signs and symptoms of Alzheimers disease
Impact of Alzheimers disease on the U.S. population, and on caregivers
Who: Alireza Atri, MD, PhD, Massachusetts General Hospital Department of Neurology and ICAD attendee
More Information: www.alz.org/ICAD
ALZHEIMERS DISEASE FACTS Alzheimers disease, the seventh-leading cause of death in the U.S., is a progressive and fatal neurodegenerative disorder characterized by problems with memory, thinking, and behavior that eventually becomes severe enough to affect work, lifelong hobbies, or social life. Every 70 seconds, someone in the U.S. develops Alzheimers disease, and by 2050, someone will develop it every 33 seconds. Approximately 10 million of the 78 million U.S. baby boomers who are alive today can expect to develop Alzheimers disease, a condition that often disrupts relationships and life plans. This radio media tour is made available by Forest Laboratories, Inc., makers of Namenda (memantine HCl), indicated for the treatment of moderate to severe Alzheimers disease.
